GBA Presents: House of Gummy-!

Discussion in 'Stocks' started by stonedinvestor, May 13, 2023.

    1. LOADING DOCK-->

      DICE DICE Therapeutics, Inc.

      $29.46 0.79 (+2.76%)11:13 AM 03/31/23


      #16042 Mar 31, 2023 Report
      Reply Share

      #2068 Jun 21, 2023 Report
      Reply Share
    2. [​IMG]
      stonedinvestor I hate being forced into names when the market is not cooperating.

      But this DICE it maybe last chance express here--

      DICE DICE Therapeutics, Inc.

      $32.67-0.33 (-1.00%)4:00 PM 04/21/23
      NASDAQ | $USD | Pre-Market: $33.50 +0.83 (+2.54%) <-------:caution:

      #16817 Apr 24, 2023 Report
      Reply Share

      #2069 Jun 21, 2023 Report
      Reply Share
    3. [​IMG]
      stonedinvestor Back in just under $35 // should of been $29 as you can see///

      Can't say I did not hold your hand through the whole process.


      A-DICE Therapeutics, Inc. (DICE)

      NasdaqGM - NasdaqGM Real Time Price.
      34.77+2.11 (+6.46%)
      As of 12:06PM EDT.

     
    #3071     Jul 10, 2023
  1. BECAUSE WE NAILED THE TRADE TWICE I WANT TO NOMINATE DICE AS GBA TRADE OF THE YEAR! WE HAVE HAD LARGER WINNERS BUT IT FEELS GOOD TO GIVE THE CHILDREN SO MUCH WARNING TWICE!!! :cool:
     
    #3072     Jul 10, 2023



  2. UPDATE-


    $62
     
    #3073     Jul 10, 2023



  3. LET THIS COME IN MORE AND WE GET A 2ND CHANCE!!!
     
    #3074     Jul 10, 2023



  4. HOLD?

    CF CF Industries Holdings, Inc.

    $70.82-1.03 (-1.43%)9:47 AM 07/10/23
    NYSE | $USD | Realtime
     
    #3075     Jul 10, 2023







  5. THIS STOCK MUST OF SPLIT?

    IT'S AT A 52 WEEK HIGH AND UP 150% IN 6 MONTHS OR SO?

    WHATS'S GOING ON HERE :wtf:

    LFMD LifeMD, Inc.

    $4.920.35 (+7.66%)9:48 AM 07/10/23
    NASDAQ | $USD | Realtime
     
    #3076     Jul 10, 2023
  6. Mattel, Inc. (MAT) $21.20 HOD ON THE WAY TO $25
    NasdaqGS - NasdaqGS Real Time Price.
    20.98+0.50 (+2.44%)
    As of 09:57AM EDT.
     
    #3077     Jul 10, 2023
  7. TOUCHDOWN- HOW DID I MISS THIS.

    Management Commentary
    “LifeMD started the year with tremendous performance in the first quarter of 2023. We exceeded our previous guidance for both Revenue and Consolidated Adjusted EBITDA, with record performance in both metrics. Importantly, and consistent with guidance we gave throughout 2022, our telehealth business returned to meaningful double digit revenue growth with sequential revenue in the first quarter of 2023 increasing 23% versus the fourth quarter of 2022. WorkSimpli continued to outperform, achieving EBITDA margins in the first quarter exceeding 20%, while executing numerous impactful launches, including expansion of its products to numerous new languages, launching digital signature capabilities, and executing several product enhancements to its product and forms suite.” said Justin Schreiber, Chairman & CEO of LifeMD. “Looking ahead, we remain extremely well positioned to accelerate our performance in 2023 anchored by strong lifestyle healthcare brands, a rapidly growing Virtual Primary Care (VPC) platform, recent successful launches of new product offerings, a healthy B2B pipeline, a strengthened balance sheet, and a highly profitable subsidiary producing significant cash flow that can help us further accelerate the core telehealth business.”

    LifeMD CFO Marc Benathen, commented: “Our first quarter performance was extremely strong, exceeding guidance on both the top- and bottom-line, while producing substantial sequential revenue growth across both our telehealth and WorkSimpli businesses. Operationally, we also achieved several record performance levels, including consolidated Gross Margins of 87%, continued reductions in our G&A, Selling & Marketing spend as a percentage of Revenue. and a 40% improvement in First Year Lifetime Patient Value (LTV). We are particularly proud to report tat net of Accounts Payable timing, LifeMD’s cash burn reduced to just $678K and we are well on our way to achieving our guidance of Free Cash Flow positivity by mid-2023. Additionally, during the quarter we completed a significant institutional debt financing arrangement with Avenue Capital, providing up to $40 million of total funding capacity, which we believe puts us a in a very strong long-term capital position when combined with our growing profits.”

    Financial Guidance
    For the Second Quarter 2023, the Company expects:

    • Consolidated Revenue to total between $35.0 million and $36.0 million

    • Consolidated Adjusted EBITDA between $2.5 and $3.5 million
    For the Full Year 2023, the Company re-affirms guidance of:

    • Consolidated Revenue to total between $140.0 million and $150.0 million

    • Consolidated Adjusted EBITDA between $12.0 and $18.0 million
     
    #3078     Jul 10, 2023
  8.  
    #3079     Jul 10, 2023
  9. #3080     Jul 10, 2023